Advertisement

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Nizar J. Bahlis, Heather Sutherland, Darrell White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina Gasparetto, Aldo Del Col, Paola Neri, Donna Reece, Michael Kauffman, Sharon Shacham, T. J. Unger, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah and Christine Chen

Article Information

Citation 
vol. 132 no. 24 2546-2554
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted June 19, 2018
  • Accepted October 17, 2018
  • Published online December 13, 2018.

Article Versions


Contributors 
  • Nizar J. Bahlis, 1Charbonneau Cancer Research Institute, Calgary, AB, Canada;
  • Heather Sutherland, 2Vancouver General Hospital, Vancouver, BC, Canada;
  • Darrell White, 3QEII Health Sciences Center, Dalhousie University, Halifax, NS, Canada;
  • Michael Sebag, 4Royal Victoria Hospital, Montreal, QC, Canada;
  • Suzanne Lentzsch, 5Multiple Myeloma and Amyloidosis Service, Columbia University, New York, NY;
  • Rami Kotb, 6Cancer Centre Manitoba, Winnipeg, MB, Canada;
  • Christopher P. Venner, 7Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada;
  • Cristina Gasparetto, 8Duke University Cancer Center, Durham, NC;
  • Aldo Del Col, 9Myeloma Canada, Dorval, QC, Canada;
  • Paola Neri, 1Charbonneau Cancer Research Institute, Calgary, AB, Canada;
  • Donna Reece, 10Princess Margaret Cancer Center, Toronto, ON, Canada; and
  • Michael Kauffman, 11Karyopharm Therapeutics Inc, Newton, MA
  • Sharon Shacham, 11Karyopharm Therapeutics Inc, Newton, MA
  • T. J. Unger, 11Karyopharm Therapeutics Inc, Newton, MA
  • Jacqueline Jeha, 11Karyopharm Therapeutics Inc, Newton, MA
  • Jean-Richard Saint-Martin, 11Karyopharm Therapeutics Inc, Newton, MA
  • Jatin Shah, 11Karyopharm Therapeutics Inc, Newton, MA
  • Christine Chen, 10Princess Margaret Cancer Center, Toronto, ON, Canada; and

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output